Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the presentation of chemotherapy-induced anagen effluvium as either diffuse or patterned hair loss and reports no new clinical findings.

This study suggests that chemotherapy-induced anagen effluvium represents patterned hair loss, with most patients retaining hairlines, but patterns do not vary significantly by age, symptoms, or chemotherapy type.

The abstract does not provide any specific research findings or results, but rather serves as a promotional description for IP Innovative Publication Pvt Limited, highlighting their services and publication offerings in medical journals and related fields from Delhi, India.

This paper discusses anagen effluvium, a reversible non-scarring hair loss often triggered by certain chemotherapy drugs, but presents no new clinical results.

This review elaborates on the skin side effects of chemotherapy and emphasizes identifying and managing both common and life-threatening skin reactions, without presenting new clinical findings.

Some drugs can cause hair loss or growth, but hair usually returns to normal after stopping the drug.

This article reviews anagen effluvium, a type of non-scarring alopecia that affects both men and women, often induced by chemotherapy or radiation, and discusses diagnostic approaches but reports no new clinical findings.

This chapter reviews common drug-related and systemic disorder-induced alopecias, focusing on their epidemiology, causes, symptoms, diagnosis, and treatment, but reports no new findings.

The paper concludes that the patchiness of alopecia areata is likely due to when the immune attack happens in the hair growth cycle.

Taking too much Albendazole can cause hair loss and other serious side effects.

Taking too much Albendazole can cause hair loss and other serious side effects.

This article reviews therapeutic methods for managing non-cicatricial alopecia associated with various conditions and provides no new clinical results.

This study reports that chemotherapy-induced hair loss affects up to 65% of patients, typically within 1 to 3 weeks of treatment, while scalp cooling may help prevent severe hair loss with taxane-based therapies.

This review discusses types and prevention measures for chemotherapy-induced hair loss, highlighting scalp cooling as the most extensively used method to help prevent this condition, and reports no new clinical results.

In this study, researchers observed that the YH complex, made from Astragalus membranaceus and Cinnamomum cassia, promoted hair regrowth and increased hair shaft thickness in mice, potentially through increased growth factors and Wnt/β-catenin signaling, suggesting its use for treating various forms of hair loss.

This review examines the anatomy and physiology of hair, focusing on the hair growth cycle and various types of alopecia, using animal models such as mice and rats to study the condition's pathophysiology and aid in developing new treatments.

Terbinafine 250 mg is the most effective treatment for fungal nail infections.

This review discusses the causes, clinical presentation, and management of anagen effluvium, emphasizing its psychological impact and the need for empathy and practical support, but reports no new results.

This research successfully established a novel mouse model for anagen effluvium using BrdU treatment, which induced hair loss and pathological changes mimicking human symptoms.

This study reviews drug-induced hair changes, noting that hair loss often reverses after stopping the drug, but permanent alopecia cases post-chemotherapy are rising.

This review describes the variety of mucocutaneous side effects caused by antineoplastic chemotherapy, with emphasis on skin, nails, and mucous membranes, while highlighting potential severity and the possibility of needing to adjust or interrupt treatment in rare cases; it presents no new clinical results.

Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.

This review discusses the link between medication use and hair loss and emphasizes the need for further research into other potential causes, reporting no new clinical results.

Hair loss in children can be caused by fungal infections, trauma, autoimmune disorders, or stress, and treatments vary depending on the cause.

This article addresses an unusual side effect of azathioprine but provides no abstract or detailed results, focusing instead on a specific dermatological perspective.

This article presents two cases of anagen effluvium following oral albendazole use and summarizes previously reported cases, suggesting this side effect may occur with this drug.

In this case report, azathioprine induced sudden hair loss and pancytopenia in a 42-year-old female patient, but discontinuing the drug and providing supportive care resulted in complete recovery and hair regrowth within 2.5 months.

In this report, researchers document a rare case of a 16-year-old female on azathioprine presenting with both anagen effluvium and plica neuropathica, highlighting a unique instance of overlapping hair conditions potentially linked to medication use.

This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.

This study found that topical EGF-liposomal solution may protect hair follicles from chemotherapy-induced damage by inducing a catagen-like stage in a mouse model.